^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    1d
    NRG-LU005: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P3, N=544, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2029
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    1d
    Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. (PubMed, ESMO Open)
    MSI-like GES does not identify a population with higher sensitivity to immune checkpoint plus angiogenesis inhibition. However, responses are promising in patients with MSI tumors and, to a lesser extent, in patients without liver metastasis regardless of MSI status.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study (clinicaltrials.gov)
    P1, N=3, Terminated, Mayo Clinic | Trial completion date: Jan 2026 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Feb 2025; low/slow accrual
    Trial completion date • Trial termination • Trial primary completion date
    |
    IMC-001
    1d
    PD-L1 PET-imaging During CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Dec 2025
    Enrollment closed • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab)
    1d
    Clinical Efficacy and Safety of Gemcitabine-Cisplatin Combination in Metastatic Gallbladder Cancer: A Prospective Study from North India. (PubMed, J Gastrointest Cancer)
    Gemcitabine-cisplatin remains effective and tolerable in metastatic GBC. Despite the emergence of Gemcitabine-Cisplatin with durvalumab as new standard, this prospective dataset provides valuable real-world outcomes from a high-incidence region with limited access to immunotherapy.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    2d
    Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, University of Arizona | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
    2d
    DREAM: Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Sep 2028 | Trial primary completion date: Apr 2028 --> Sep 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab)
    2d
    BAT7104 Injection in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=86, Completed, Bio-Thera Solutions | Recruiting --> Completed | N=42 --> 86
    Trial completion • Enrollment change
    3d
    A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting | Trial completion date: Mar 2028 --> Dec 2028
    Enrollment open • Trial completion date • Platinum resistant
    |
    paclitaxel
    3d
    Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab (clinicaltrials.gov)
    P2, N=176, Recruiting, Fondazione Ricerca Traslazionale | Trial primary completion date: May 2024 --> May 2026 | Trial completion date: Apr 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    3d
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=105, Not yet recruiting, BioNTech SE
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan • pumitamig (BNT327)
    4d
    A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)